Mark G. Bock

5.4k total citations · 1 hit paper
109 papers, 3.8k citations indexed

About

Mark G. Bock is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Mark G. Bock has authored 109 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 34 papers in Cellular and Molecular Neuroscience and 24 papers in Organic Chemistry. Recurrent topics in Mark G. Bock's work include Neuropeptides and Animal Physiology (29 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (23 papers) and Chemical Synthesis and Analysis (20 papers). Mark G. Bock is often cited by papers focused on Neuropeptides and Animal Physiology (29 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (23 papers) and Chemical Synthesis and Analysis (20 papers). Mark G. Bock collaborates with scholars based in United States, United Kingdom and Switzerland. Mark G. Bock's co-authors include Robert M. DiPardo, Roger Freidinger, B. Evans, Kenneth E. Rittle, Daniel F. Veber, Willie L. Whitter, Paul Anderson, E. J. Corey, Raymond S.L. Chang and Victor J. Lotti and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Biochemistry.

In The Last Decade

Mark G. Bock

107 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

1988 1.2k citations B. Evans, Kenneth E. Rittle et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark G. Bock United States	29	1.9k	1.8k	875	330	326	109	3.8k
Raymond S.L. Chang United States	31	2.7k 1.4×	1.6k 0.9×	1.6k 1.8×	277 0.8×	374 1.1×	114	4.7k
Robert M. DiPardo United States	21	1.5k 0.8×	1.4k 0.8×	680 0.8×	228 0.7×	260 0.8×	57	2.7k
H. Timmerman Netherlands	35	2.5k 1.3×	685 0.4×	525 0.6×	107 0.3×	210 0.6×	146	4.3k
Henk Timmerman Netherlands	36	2.4k 1.3×	517 0.3×	799 0.9×	405 1.2×	171 0.5×	112	4.2k
H. Timmerman Netherlands	26	1.5k 0.8×	614 0.3×	477 0.5×	167 0.5×	286 0.9×	91	3.1k
William J. Greenlee United States	34	2.2k 1.1×	2.0k 1.1×	642 0.7×	251 0.8×	338 1.0×	161	4.5k
Brian W. Metcalf United States	34	2.5k 1.3×	963 0.5×	834 1.0×	165 0.5×	364 1.1×	81	4.9k
Abdul H. Fauq United States	45	3.0k 1.5×	780 0.4×	734 0.8×	749 2.3×	610 1.9×	121	5.7k
B. Evans United States	21	1.6k 0.8×	1.4k 0.8×	660 0.8×	232 0.7×	264 0.8×	56	2.9k
Kenneth E. Rittle United States	20	1.3k 0.7×	1.3k 0.8×	585 0.7×	213 0.6×	278 0.9×	38	2.5k

Countries citing papers authored by Mark G. Bock

Since Specialization

Citations

This map shows the geographic impact of Mark G. Bock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Bock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Bock more than expected).

Fields of papers citing papers by Mark G. Bock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Bock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Bock. The network helps show where Mark G. Bock may publish in the future.

Co-authorship network of co-authors of Mark G. Bock

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Bock. A scholar is included among the top collaborators of Mark G. Bock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Bock. Mark G. Bock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrison, David, Andy Billinton, Mark G. Bock, et al.. (2025). Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders. RSC Medicinal Chemistry. 16(11). 5318–5332.

Smolak, Pamela J., MyTrang Nguyen, John R. Doedens, et al.. (2024). Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. Journal of Pharmacology and Experimental Therapeutics. 388(3). 798–812. 9 indexed citations

Auberson, Yves P., Thomas Troxler, Xuechun Zhang, et al.. (2014). Ergoline‐Derived Inverse Agonists of the Human H3 Receptor for the Treatment of Narcolepsy. ChemMedChem. 9(8). 1683–1696. 6 indexed citations

Auberson, Yves P., Thomas Troxler, Xuechun Zhang, et al.. (2014). From Ergolines to Indoles: Improved Inhibitors of the Human H3 Receptor for the Treatment of Narcolepsy. ChemMedChem. 10(2). 266–275. 2 indexed citations

Tang, Cuyue, Brian Carr, Bennett Ma, et al.. (2008). CYP2C75-Involved Autoinduction of Metabolism in Rhesus Monkeys of Methyl 3-Chloro-3′-fluoro-4′-{(1 R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1′-biphenyl-2-carboxylate (MK-0686), a Bradykinin B1 Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 325(3). 935–946. 6 indexed citations

Su, Dai‐Shi, Bang-Lin Wan, Kathy Murphy, et al.. (2008). 2-Aminobenzophenones as a Novel Class of Bradykinin B₁Receptor Antagonists. Journal of Medicinal Chemistry. 51(13). 3946–3952. 13 indexed citations

Kuduk, Scott D., Christina N. Di Marco, Ronald K. Chang, et al.. (2006). 5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists. Bioorganic & Medicinal Chemistry Letters. 16(10). 2791–2795. 10 indexed citations

Hess, J. Fred, Richard Z. Chen, Patricia J. Hey, et al.. (2006). Generation and characterization of a humanized bradykinin B1 receptor mouse. Biological Chemistry. 387(2). 195–201. 6 indexed citations

Kuduk, Scott D., Ronald K. Chang, Christina Ng, et al.. (2005). Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridine series. Bioorganic & Medicinal Chemistry Letters. 15(17). 3925–3929. 14 indexed citations

10.

Ha, Sookhee, C. Meacham Harrell, Ray Chang, et al.. (2005). Binding modes of dihydroquinoxalinones in a homology model of bradykinin receptor 1. Biochemical and Biophysical Research Communications. 331(1). 159–166. 19 indexed citations

11.

Hess, J. Fred, Richard W. Ransom, Zhizhen Zeng, et al.. (2004). Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model. Journal of Pharmacology and Experimental Therapeutics. 310(2). 488–497. 19 indexed citations

12.

DiPardo, Robert M., Michael A. Patane, Theodore P. Broten, et al.. (2001). Cyclic imides as potent and selective α-1A adrenergic receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 11(14). 1959–1962. 6 indexed citations

13.

Lagu, Bharat, John M. Wetzel, Carlos Forray, Michael A. Patane, & Mark G. Bock. (2000). Determination of the relative and absolute stereochemistry of a potent and α1A-selective adrenoceptor antagonist. Bioorganic & Medicinal Chemistry Letters. 10(24). 2705–2707. 2 indexed citations

14.

Williams, Peter, et al.. (1998). Progress in the Development of Oxytocin Antagonists for Use in Preterm Labor. Advances in experimental medicine and biology. 395. 473–479. 32 indexed citations

15.

Bock, Mark G., Roger Freidinger, Edward V. Lis, et al.. (1998). Nonpeptide oxytocin antagonists: Potent, orally bioavailable analogs of L-371,257 containing A 1-R-(pyridyl)ethyl ether terminus. Bioorganic & Medicinal Chemistry Letters. 8(21). 3081–3086. 9 indexed citations

16.

Williams, Peter, Mark G. Bock, Roger D. Tung, et al.. (1992). Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product. Journal of Medicinal Chemistry. 35(21). 3905–3918. 28 indexed citations

17.

Clineschmidt, Bradley V., et al.. (1992). Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues. Life Sciences. 50(25). 1953–1958. 60 indexed citations

18.

Bock, Mark G., Robert M. DiPardo, Paul Williams, et al.. (1990). Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide. Journal of Medicinal Chemistry. 33(9). 2321–2323. 26 indexed citations

19.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1988). Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines. Journal of Medicinal Chemistry. 31(1). 176–181. 16 indexed citations

20.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1987). Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini. Journal of Medicinal Chemistry. 30(10). 1853–1857. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact